Skip To Main Content
Michael Barish on Muck Rack

Michael Barish

As seen in: BioRxiv, Cell Reports Medicine, Healio, City of Hope, ONCOLOGY journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Michael

Contact Michael, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Nimotuzumab Plus Image-Guided RT May Be Feasible in Older LACSCC Population

|
By Sonia Jain, Roman Fabbricatore, Russ Conroy, Michael Barish
| ONCOLOGY journal Verified
Among older patients with locally advanced cervical squamous cell carcinoma (LACSCC), the combination of nimotuzumab with image-guided radiotherapy and brachytherapy was well-tolerated and displayed promising survival outcomes, according to findings from a prospective, single-arm phase 2 trial (NCT04976478) published in the International Journal of Radiation Oncology, Biology, and Physics.
Open in Who Shared Issue with article?

Zanidatamab-Based Regimens Exhibit Improved PFS in Gastroesophageal Cancers

|
By Sonia Jain, Roman Fabbricatore, Ariana Pelosci Verified, Michael Barish
| ONCOLOGY journal Verified
The addition of zanidatamab-hrii (Ziihera) to chemotherapy with or without tislelizumab (Tevimbra) exhibited significantly improved survival outcomes, including progression-free survival (PFS) and overall survival (OS), compared with chemotherapy and trastuzumab (Herceptin) as a frontline treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma, encompassing cancers of the stomach, gastroesophageal junction, and esophagus, in the phase 3...
Open in Who Shared Issue with article?

What is the Current State of ADC Treatment in EGFR-Amplified Glioblastoma?

|
By Sonia Jain, Michael Barish, Tim Cortese, Russ Conroy
| ONCOLOGY journal Verified
EGFR amplification can be observed in half of the population of patients who have glioblastoma, according to Sonia Jain, PhD. For that reason, developing an antibody-drug conjugate (ADC) that targets EGFR is important, although current patient outcomes are not optimal.
Open in Who Shared Issue with article?
See all 20 articles